Expect a Limited Role for Zuranolone in Postpartum Depression
April 2026
Zuranolone (Zurzuvae) will be the first med approved for treating postpartum depression.
Zuranolone mimics the hormone allopregnanolone, which interacts with GABA receptors. This hormone abruptly dips around childbirth...possibly leading to major depression.
Zuranolone is dosed orally once daily for 14 days and starts to improve depression symptoms within days. In contrast, SSRIs take at least 1 to 2 weeks to start working.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive